A Study of LY3405105 in Participants With Advanced Cancer
The main purpose of this study is to investigate the safety of LY3405105 in participants with advanced cancer. The study has two parts (A and B). Participants will only enroll in one part.
Your participation in this trial could last 6 months or longer depending on how you and your tumor respond.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Participants must have evidence of a diagnosis of a solid tumor cancer that is advanced and/or metastatic
Participants must have available archived tissue for exploratory biomarker analysis
Participants must have adequate organ function
Participants must have discontinued all previous treatments for cancer and recovered from their side effects
Participants must be able to swallow capsules/tablets
Participants must not have symptomatic central nervous system (CNS) malignancy or metastasis
Participants must not have symptomatic HIV, Hepatitis A, B, or C
Participants must not have congestive heart failure
Participants must not be breastfeeding